Jonathan Dworkin, PhD, professor of microbiology & immunology at the Vagelos College of Physicians and Surgeons, has been named a fellow of the American Association for the Advancement of Science.
New details about the way this important molecule takes on tasks beyond sensing calcium could spur the develop of new drugs for breast cancer and other diseases.
BeatProfiler, a new research tool invented by Columbia bioengineers with the help of AI, speeds and simplifies the analysis of engineered heart tissue in the laboratory.
A new study has found that up to 20% of aggressive brain cancers are fueled by overactive mitochondria and new drugs in development may be able to starve the cancers.
New images of Wnt, a signaling protein mutated in some cancers, in complex with its specific carrier, reveals atomic-level details of the molecules and a potential new drug target.
A new study conducted at Columbia and other centers found that 80% of patients with a type of slow-growing lymphoma achieved a complete remission with a single infusion of CAR T-cell immunotherapy.
In children with certain autism mutations, the diversity and severity of symptoms are often related to the identity and properties of gene units, called exons, targeted by the mutations.
A study of more than 1 million patients has found no increased risk of COVID-19 diagnosis, hospitalization, or complications for users of two common anti-hypertensive medications.
Columbia researchers created a new technology using synthetic llama antibodies to protect endangered proteins inside cells. The technology could treat dozens of diseases.
Researchers at Columbia, UCLA, and Northeastern have begun helping the FDA in its effort to monitor the safety and effectiveness of vaccines, including COVID-19 vaccines, and other biologic products.